MX2014002873A - Fitocanabinoides que pueden usarse en el tratamiento del cancer. - Google Patents

Fitocanabinoides que pueden usarse en el tratamiento del cancer.

Info

Publication number
MX2014002873A
MX2014002873A MX2014002873A MX2014002873A MX2014002873A MX 2014002873 A MX2014002873 A MX 2014002873A MX 2014002873 A MX2014002873 A MX 2014002873A MX 2014002873 A MX2014002873 A MX 2014002873A MX 2014002873 A MX2014002873 A MX 2014002873A
Authority
MX
Mexico
Prior art keywords
phytocannabinoids
treatment
cancer
combination
migration
Prior art date
Application number
MX2014002873A
Other languages
English (en)
Inventor
Ruth Alexandra Ross
Daniela Parolaro
Original Assignee
Gw Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gw Pharma Ltd filed Critical Gw Pharma Ltd
Publication of MX2014002873A publication Critical patent/MX2014002873A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de los fitocanabinoides en el tratamiento del cáncer. Uso de los fitocanabinoides en el tratamiento de las invasiones, la migración o las metástasis de las células tumorales. Los cánceres donde la capacidad de invasión y migración de las células es crítica para el pronóstico incluyen los tumores cerebrales, más particularmente los gliomas, y aun más particularmente el glioblastoma multiforme (GBM) y el cáncer de mama. Los fitocanabinoides tetrahidrocanabivarina (THCV) y canabidivarina (CBDV), por separado, combinadas una con otra o en combinación con otros fitocanabinoides, particularmente en combinación con canabidiol (CBD), tetrahidrocanabinol (THC), canabigerol (CBG) o sus ácidos respectivos, son particularmente útiles.
MX2014002873A 2011-09-12 2012-09-10 Fitocanabinoides que pueden usarse en el tratamiento del cancer. MX2014002873A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1115711.2A GB2494461A (en) 2011-09-12 2011-09-12 Phytocannabinoids for use in the treatment of invasive cancers or metastases
PCT/GB2012/052224 WO2013038157A1 (en) 2011-09-12 2012-09-10 Phytocannabinoids for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2014002873A true MX2014002873A (es) 2014-05-27

Family

ID=44908405

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002873A MX2014002873A (es) 2011-09-12 2012-09-10 Fitocanabinoides que pueden usarse en el tratamiento del cancer.

Country Status (6)

Country Link
US (1) US20140221469A1 (es)
AR (1) AR087842A1 (es)
GB (1) GB2494461A (es)
MX (1) MX2014002873A (es)
TW (1) TW201316985A (es)
WO (1) WO2013038157A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013164824A1 (en) 2012-05-03 2013-11-07 Magdent Ltd. Bone enhancement device and method
CA3012383C (en) * 2013-02-28 2021-03-02 Teewinot Technologies Limited Biosynthesis of cannabinoids
GB2513167B (en) 2013-04-18 2016-03-02 Otsuka Pharma Co Ltd Tetrahydrocannabivarin for use in the treatment of nausea and vomiting
GB2515312A (en) 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
US10774288B2 (en) 2013-09-18 2020-09-15 The Werc Shop, LLC Terpene-based compositions, processes, methodologies for creation and products thereby
GB2527590A (en) * 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
CN109593651A (zh) 2014-08-25 2019-04-09 蒂威诺特科技有限公司 用于大麻素化合物的同时生产的设备和方法
CA2974292C (en) 2015-01-31 2024-04-16 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
AU2016225026A1 (en) * 2015-02-27 2017-09-07 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
US12303541B2 (en) 2015-04-01 2025-05-20 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Erodium crassifolium L'Her plant extracts and uses thereof
US10960035B2 (en) 2015-04-01 2021-03-30 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Voleaui Center) Erodium crassifolium L'Her plant extracts and uses thereof
HUE049872T2 (hu) * 2015-05-07 2020-11-30 Res Grow Labs Kannabisz olaj hidrogénezése
EP3380096A4 (en) 2015-11-24 2019-10-23 Constance Therapeutics, Inc. CANNABIS OIL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US10399920B2 (en) 2016-06-01 2019-09-03 S&B Pharma, Inc. Crystalline form of cannabidiol
US10053407B2 (en) 2016-06-01 2018-08-21 S&B Pharma, Inc. Crystalline cannabidivarin
US12485129B2 (en) 2016-08-29 2025-12-02 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
MX380850B (es) 2016-08-29 2025-03-12 Canopy Growth Corp Composiciones solubles en agua que comprenden cannabinoides purificadas
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
EP3592346A4 (en) 2017-03-05 2020-12-30 The State of Isreal, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
EP3509638B1 (en) 2017-06-20 2022-01-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Cannabidiolic acid esters compositions and uses thereof
US10688191B2 (en) 2018-01-19 2020-06-23 Hr Biomed, Llc Delivery of a chemotherapy agent across the blood-brain barrier
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
AU2019251357B2 (en) 2018-04-09 2023-10-05 Portland Technology Holdings Llc Hemp extract for treatment of pain in animals
WO2020077153A1 (en) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthesis of cannabigerol
US12403114B2 (en) 2019-03-12 2025-09-02 Epm (Ip), Inc. Cannabinoid acid ester compositions and uses thereof
CA3140290A1 (en) * 2019-05-16 2020-11-19 Technion Research & Development Foundation Limited Cannabinoids and uses thereof
IL272078A (en) * 2020-01-16 2021-07-29 Can Fite Biopharma Ltd Cannabinoids for use in treatment
MX2022009219A (es) * 2020-01-27 2022-09-29 Chemtor Lp Mezclas de cannabidiol que no cristalizan.
CN111233814A (zh) * 2020-03-02 2020-06-05 福建省中科生物股份有限公司 一种萜酚类化合物zkyy-057及其制备方法和应用
IL297246A (en) * 2020-04-13 2022-12-01 Cannabics Pharmaceuticals Inc Composition and method for treating cancer with cannabinoids
IL307444A (en) * 2021-04-05 2023-12-01 The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo Preparations and methods for the treatment of cancer
WO2023062634A1 (en) * 2021-10-13 2023-04-20 G.R.I.N Ultra Ltd Compositions comprising cannabinoids and methods of use thereof in the treatment of cancer
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
CN118717985A (zh) * 2024-06-05 2024-10-01 汕头大学医学院 一种用于胶质母细胞瘤的cb2r拮抗剂及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2475183B (en) 2008-06-04 2011-11-23 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma

Also Published As

Publication number Publication date
GB2494461A (en) 2013-03-13
AR087842A1 (es) 2014-04-23
TW201316985A (zh) 2013-05-01
WO2013038157A1 (en) 2013-03-21
US20140221469A1 (en) 2014-08-07
GB201115711D0 (en) 2011-10-26

Similar Documents

Publication Publication Date Title
AR087842A1 (es) Fitocanabinoides que pueden usarse en el tratamiento del cancer
AR080454A1 (es) Fitocanabinoides en el tratamiento del cancer
CL2017001943A1 (es) Terapias de combinación para el tratamiento de cánceres
MX2015008898A (es) Metodos para el tratamiento de cancer pancreatico.
CY1121038T1 (el) Θεραπεια καρκινου μαστου
MX374488B (es) Biomarcadores y su uso en el tratamiento de condiciones relacionadas con pd-1 y pd-l1.
MX2015012922A (es) Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular.
CO6382172A2 (es) Efectos antitumorales de combinaciones cannabinoides
EA201290975A1 (ru) Применение фитоканнабиноида каннабидиварина (cbdv) для лечения эпилепсии
MX2016006119A (es) Derivados de 1-(5-terc-butil-2-aril-pirazol-3-il)-3-[2-fluoro-4-[( 3-oxo-4h-pirido[2,3 b]piracin-8-il)oxi]fenil]urea como inhibidores de raf para el tratamiento del cancer.
BR112014009276A8 (pt) uso de inibidores de tirosina quinase de bruton (btk)
MX2016012176A (es) Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.
AR088391A1 (es) Fitocanabinoides para usar en el tratamiento de cancer de mama
CL2014001158A1 (es) Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros.
UY34132A (es) Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab.
MX2014005800A (es) Mutaciones del receptor notch humano y su uso.
NI201500063A (es) Tratamiento de cáncer con pomalidomida en un individuo con daño renal
BR112013003579A2 (pt) adenovírus, células, e, métodos para tratar câncer
CL2014002975A1 (es) Método in vitro para el diagnostico y vigilancia del cáncer, que comprende determinar la razón entre las células treg y otro grupo de células t, seleccionadas de th17, th1 y/o th2.
DOP2011000282A (es) Combinaciones farmaceuticas que comprenden rdea119/bay 869766 para el tratamiento de canceres especificos
WO2011112903A3 (en) Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients
ES2659519T3 (es) Método para producir medicamentos para combatir tumores
AR092423A1 (es) Metodo de diagnostico y tratamiento del cancer dirigido a las moleculas expresadas en celulas madre cancerosas
CL2011002774A1 (es) Combinacion farmaceutica que comprende cabazitaxel y capecitabina, en forma de base, sal, hidrato o solvato; uso para el tratamiento del cancer de mama metastasico.
MX375276B (es) Biomarcadores para canceres que responden a moduladores de la actividad de hec1.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal